While CT and MRI remain the primary modalities for post-treatment follow-up, especially in high-grade or disseminated disease, tumor markers such as CEA, CA19-9, and occasionally chromogranin A may be useful for monitoring, although no marker is specific. The gene discussed is CEACAM5; the disease is neoplasm.